SCHEMBL4870787

SCHEMBL4870787

NCCCc1ccc2c(=O)[nH]cnc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 9/20 0.53
CHEK1 O14757 3/20 0.53
PIM1 P11309 2/20 0.53
ALDH1A1 P00352 1/20 0.53
RPS6KA3 P51812 1/20 0.53
IP6K1 Q92551 2/20 0.52
IP6K3 Q96PC2 1/20 0.52
IP6K2 Q9UHH9 1/20 0.52
PDPK1 O15530 1/20 0.46
CA12 O43570 1/20 0.46
ALOX15 P16050 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CA9 Q16790 1/20 0.46
TNKS2 Q9H2K2 1/20 0.46
ROCK2 O75116 1/20 0.44
KDM4A O75164 1/20 0.43
KDM4B O94953 1/20 0.43
KDM5C P41229 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
KDM5B Q9UGL1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5197904 0.80 IP6K1 (0.39) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL24617507 0.78 PARP1 (0.58) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL4066634 0.78 PARP1 (0.58) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL3796386 0.78 MAPT (0.42) ALDH1A1IP6K1IP6K3IP6K2
SCHEMBL4875349 0.78 PARP1 (0.51) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL5097264 0.77 PARP1 (0.56) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL3796388 0.75 DRD2 (0.52) ALDH1A1
SCHEMBL16538688 0.75 PARP1 (0.58) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL25275583 0.75 PARP1 (0.61) PARP1CHEK1PIM1ALDH1A1RPS6KA3
SCHEMBL4876430 0.73 PARP1 (0.53) PARP1CHEK1PIM1ALDH1A1RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders ASTEX THERAPEUTICS LIMITED (GB) 2008-11-06 US disclosed
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders ASTEX THERAPEUTICS LIMITED (GB) 2008-11-06 US disclosed
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders ASTEX THERAPEUTICS LIMITED (GB) 2008-11-06 US disclosed
EP-1814552-A2 COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS Astex Therapeutics Limited (GB) 2007-08-08 EP disclosed
WO-2006051290-A2 COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS ASTEX THERAPEUTICS LIMITED (GB) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders CNKSR1, PRKCH, PRKAR2B PARP1 2645/4885CHEK1 233/4885PIM1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.